contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


c-rad-presents-new-product-enhancements-at-estro-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

C-Rad operates in the medical technology industry and focuses on the development and manufacture of systems for radiation therapy of cancer. The company's products are aimed at healthcare institutions and oncologists. The business is present on a global level, with a main presence in Europe, North America and Asia. C-Rad was founded in 2004 and is headquartered in Uppsala, Sweden.

C-Rad

At ESTRO 2025 in Vienna, C-RAD will present new product enhancements, reflecting the company’s continued focus on empowering clinicians with tools that make a tangible difference in daily practice...

<div class="mfn-preamble"><p><strong>At ESTRO 2025 in Vienna, C-RAD will present new product enhancements, reflecting the company’s continued focus on empowering clinicians with tools that make a tangible difference in daily practice.</strong></p></div><div class="mfn-body"><p>With a clear emphasis on user experience and streamlined workflows, these new product offerings are designed to support healthcare professionals in delivering precise, efficient, and patient-centered cancer care.</p><p><strong>SGRT Solutions for Smooth Workflows</strong><br>The latest product developments reflect C-RAD’s user-first approach and dedication to improving the everyday realities of clinical work through streamlined SGRT workflows. They include:</p><ul><li><strong>Catalyst+LITE</strong> – A smart and accessible way for clinics to begin their SGRT journey, enabling high-precision motion management together with secure, tattoo-less patient setup. The new solution provides an efficient entry point into SGRT that can be seamlessly upgraded to Catalyst+ HD.</li><li><strong>Ergonomic workflow enhancements</strong> – Designed to support a smoother, more intuitive setup experience, the new ergonomic workflow features initial coarse posture correction to ensure optimal alignment, improved accessibility as well as a user-friendly setup that prioritizes clinician comfort.</li><li><strong>Customizable Graphical User Interface (GUI)</strong> – A redesigned interface designed for clarity and usability, allowing for a more streamlined experience while maintaining existing workflows and functionality.</li></ul><p>These new product enhancements strengthen C-RAD’s SGRT offering and underscore the company’s ongoing collaboration with the clinical community to meet real-world needs.</p><p><strong>Cecilia de Leeuw, CEO of C-RAD</strong>, commented: “ESTRO 2025 marks an exciting milestone for C-RAD. We’ve worked closely with our customers to ensure that everything we present — from product updates to how we communicate — is grounded in what they truly need. These launches reflect the strength of that collaboration and our commitment to making cancer care safer, more precise, and more personal. This is the essence of C-RAD: solution-driven, purposeful, and deeply connected to those we serve.”</p><p>C-RAD welcomes all ESTRO 2025 attendees to visit Booth 860 to explore the latest product updates.</p></div><div class="mfn-footer mfn-contacts mfn-e520b92ae86a"><p><strong class="mfn-heading-1">For further information:</strong></p><hr><p>Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, <a rel="noopener" href="mailto:investors@c-rad.com">investors@c-rad.com</a><br>Linda Frölén, CFO, +46 (0)703 03 32 53, <a rel="noopener" href="mailto:investors@c-rad.com">investors@c-rad.com</a></p></div><div class="mfn-footer mfn-about mfn-1fc3b360975a"><p><strong class="mfn-heading-1">About C-RAD</strong></p><hr><p>C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.</p><p>C-RAD AB is listed on NASDAQ Stockholm.</p><p>For more information on C-RAD, please visit&nbsp;<a rel="noopener" href="http://www.c-rad.com/">http://www.c-rad.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/1d4ac22c-6b82-4050-8b3f-185a74d3b62a/c-rad-presents-new-product-enhancements-at-estro-2025.pdf" class="mfn-generated mfn-primary">C-RAD Presents New Product Enhancements at ESTRO 2025</a></p></div>